LDL-c: Done Deal, Next Epigenetics?

Symposium to be held at European Society of Cardiology 2018 Meeting

Saturday, August 25, 2018: 15:30 – 16:30 hrs (Munich, Germany time)

Agenda

• Introduction, Ulrich Laufs, MD, University of Leipzig Medical Center, Leipzig, Germany
• The real residual risk in patients with CVD & diabetes: The promise of epigenetics, Erik Stroes, MD, Academic Medical Centre, Amsterdam, The Netherlands
• Understanding Epigenetics: The potential rationale for BET inhibition in management of CVD, Jorge Plutzky, MD, Brigham & Women’s Hospital, Boston, USA
• A clinical view on BET inhibition in targeting residual risk in CVD and Diabetes , Kausik Ray, MD, Imperial College London, London, United Kingdom
• Panel discussion, Ulrich Laufs, MD, Kausik Ray, MD

By the way, I don't see the ERA-EDTA 2018 Symposium "Epigenetics in CKD & CVD: A potential breakthrough therapy" from last month on the https://pace-cme.org/bet-inhibition/ website yet.